PTO/SIN21 (09-04)

## RECEIVED **CENTRAL FAX CENTER**

	JUN 1 7 2005	Approved 1	PTO/SIV21 (09-04) for use through 07/31/2006. OMB 0051-0031	
Under the Pareswerk Reduction Act of 1995, no. o	ersons pro required to respond to a col	alent and Tradomark C action of Information w	Office; U.S. DEPARTMENT OF COMMERCE pless it displays a valid OMB control number.	
SA PERMANENTAL SECURITION OF THE PER	Application Number	10/714,447		
TRANSMITTAL	Filing Date	November 17, 2003		
FORM	First Named Inventor	Edward Roberts		
, 5.4	Art Unil	1624		
the state of the s	Examiner Namo	Emily B. Demhardt		
(to be used for all correspondence after initial filing.  Total Number of Pages in This Submission 6	Attorney Docket Number	A1479-3P US (7567/80871)		
ENCLOSURES (Check all that apply)				
Fee Transmittal Form  Feo Attached  Amundmunt/Repty  After Final  Affidavits/ductaration(s)  Extension of Time Request  Express Abundonment Request  Information Disclosure Statement  Cortified Copy of Priority  Document(s)  Repty to Missing Parts/ Incomplete Application  Repty to Missing Parts/ Incomplete Application  Repty to Missing Parts/ Index 37 CFR 1.52 or 1.53	Drawing(s)  Licensing-related Papers  Polition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence / Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Landscape Table on Correspondence  Remarks	Address Requ	After Allowance Communication to TC Appeal Communication to Record of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): lest for Reconsideration	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
Firm Namo AstraZenuca				
Signaturo	A118			
Printed name George A Gilbert				
Date Juse 17, 2005		Reg. No. 35,881		
CERTIFICATE OF TRANSMISSION/MAILING				
I hamby carlly that this concepondence is being feasimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first drass mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the dute shown below:				
Signaturo (Xis Ophtor)				
Typed or crinted name Liz Ashlon		· · · · · · · · · · · · · · · · · · ·	Date June 17, 2005	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a banefit by the public which is to file (and by the USPTO to places) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ant/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Oppathesh of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the farm, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER
JUN 1 7 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/714,447	Applicant: Roberts et al.	
Filing Date: November 17, 2003	Attorney Docket No.: A1479-3P US (7567/80871)	
Examiner: Emily B. Bernhardt	Group Art Unit: 1624	
Customer No.: 22466	Confirmation No.: 9363	
Title: Novel compounds with analgesic	effect	

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on June 17, 2005

Signature Liz Ashton

Mail Stop AF Commissioner for Patents P.O. Box 1450 Nexandria, VA 22313-1450

## Request for Reconsideration

Sir:

In response to the Final Office Action dated March 22, 2005, no amendment is made to the application and Applicants respectfully request Examiner's reconsideration of the pending claim in view of the arguments made in the Remarks section.

Listing of Claims begins on page 2 of this paper.

Remarks begin on page 4 of this paper.